⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24267913 | 0.75 | CYP11B1 (0.35) | — | |
| SCHEMBL25374541 | 0.73 | — | — | |
| SCHEMBL15202017 | 0.73 | — | — | |
| SCHEMBL24268152 | 0.69 | KDM4E (0.37) | — | |
| SCHEMBL18250282 | 0.68 | HSP90AA1 (0.49) | — | |
| Hydrochloric Acid SCHEMBL5657016 | 0.67 | HSP90AA1 (0.35) | — | |
| SCHEMBL31609041 | 0.67 | ALDH1A1 (0.39) | — | |
| SCHEMBL29200940 | 0.65 | ADORA2A (0.42) | — | |
| SCHEMBL24268157 | 0.65 | HCAR1 (0.40) | — | |
| SCHEMBL23638732 | 0.65 | HSP90AA1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999715-B2 | ASK1 inhibiting agents | BIOGEN MA INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-3837251-B1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC (US) | 2023-06-21 | — | — | EP | disclosed |
| US-20210317103-A1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC. | 2021-10-14 | — | — | US | disclosed |
| CN-113227070-A | ASK1 inhibitors | 比奥根MA公司 | 2021-08-06 | — | — | CN | disclosed |
| EP-3858824-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3858824-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3837251-A1 | ASK1 INHIBITING AGENTS | Biogen MA Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| EP-3363797-B1 | ORAL DOSAGE FORM OF APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3363797-B1 | ORAL DOSAGE FORM OF APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2020-12-02 | — | — | EP | disclosed |
| WO-2020036949-A1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2020-02-20 | — | — | WO | disclosed |
| US-20130012521-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012521-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012521-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| CN-102482257-A | Apoptosis signal-modulating kinase inhibitors | GILEAD SCIENCES INC | 2012-05-30 | — | — | CN | disclosed |
| EP-2454250-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011008709-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011008709-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |